One of the reasons I have been following this news is rather selfish in that the study does require the use of UVB Narrow Band and we (Amjo Corp) are a leader in the sale of UVB Narrow Band Products for the treatment of Vitiligo, Psoriasis, Eczema and many other skin challenges such as CTCL, Mycosis Fungoides and some forms of Pruritus.
I did post a little about this with a Video in January <Click Here>
The text that follows is borrowed from an article at PharmaLive
“Drug trial in skin disorder affecting 45 million globally to commence in USA, Europe.
A new treatment for one of the world’s most distressing skin disorders is about to commence trials across the USA and Europe. The USA’s Food and Drug Administration (FDA) has agreed to allow a pilot trial of the new drug SCENESSE® (afamelanotide) to determine whether it can help repigment the skin of patients with vitiligo.
Vitiligo is an autoimmune disease which causes patchy loss of skin color in ‘lesions’ which spread over the body. Onset of the disease can be sudden and lesions can spread quickly. Vitiligo affects all races but is most visible in individuals with darker skin. Global studies have shown vitiligo can have a significant impact upon an individual’s quality of life as their skin inexplicitly and dramatically changes color.
SCENESSE®, an injectable which mimics the body’s natural ability to activate the skin pigment melanin, will be trialled in nonsegmental vitiligo; the most common form of the disease which affects over 45 million individuals globally.
The drug will be tested in combination with narrow-band ultraviolet B (NB-UVB) light therapy, a recognised treatment but one which takes up to 18 months of twice- or thrice-weekly clinical visits to return pigment to the skin. The goal of the trial is to determine whether SCENESSE® will reduce the dose of radiation (NB-UVB) and the time required to reactivate skin pigment producing cells in vitiliginous lesions.”
You can read the entire article at http://pharmalive.com/News/index.cfm?articleid=765588&categoryid=21